{"filing":{"accession_number":"0001193125-26-347907","cik":"0001840229","ticker":"INKT","company_name":"MiNK Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"inkt-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/inkt-20260813.htm"},"events":[{"id":27517,"run_id":25087,"accession_number":"0001193125-26-347907","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"MiNK Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly net loss ($3.1 million vs. $4.2 million prior year), cash position ($8.8 million), and per-share loss metrics ($0.62 vs. $1.06 prior year), along with clinical updates on the lead program agenT-797. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and clinical progress.","company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29094,"accession_number":"0001193125-26-347907","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MiNK Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly net loss ($3.1 million vs. $4.2 million prior year), cash position ($8.8 million), and per-share loss metrics ($0.62 vs. $1.06 prior year), along with clinical updates on the lead program agenT-797. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:41:40.960897+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29094,"accession_number":"0001193125-26-347907","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MiNK Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly net loss ($3.1 million vs. $4.2 million prior year), cash position ($8.8 million), and per-share loss metrics ($0.62 vs. $1.06 prior year), along with clinical updates on the lead program agenT-797. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:41:40.960897+00:00","company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","filing_date":"2026-08-13"}]}